ライフサイエンスコーパス: platelet factor 4

1 ene for another platelet-specific chemokine, platelet factor 4.

2 llebrand factor (VWF), thrombospondin-1, and platelet factor 4.

3 :Ag) and propeptide (VWFpp), P-selectin, and platelet factor 4.

4 , with more than 80% of them also containing platelet factor 4.

5 subjects with severe asthma, whereas plasma platelet factor 4, a second platelet activation marker,

6 rollary of these concepts is that disrupting platelet factor 4 and beta(2)GPI conformation (or ultral

7 and analyzed for sCD40L, interleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of p

8 In contrast, platelet factor 4 and beta-thromboglobulin do not appear

9 HTTLPR l/l genotype had significantly higher platelet factor 4 and beta-thromboglobulin levels.

10 re more cognitively impaired, and had higher platelet factor 4 and beta-thromboglobulin levels; cardi

11 gin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not inc

12 of CPB and was similar to that observed for platelet factor 4 and beta-thromboglobulin.

13 th antibodies to complexes that form between platelet factor 4 and glycosaminoglycan (GAG) side chain

14 tibodies against multimolecular complexes of platelet factor 4 and heparin.

15 Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft

16 ibodies over 1 week sustained high levels of platelet factor 4 and serotonin.

17 ts demonstrated that P-selectin, fibrinogen, platelet factor 4 and vascular endothelial growth factor

18 correlated with plasma levels of P-selectin, platelet factor 4, and platelet basic protein in the pop

19 ble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-activating factor, which

20 analyzed with ELISA for soluble P-selectin, platelet factor 4, and thrombospondin-1.

21 binding proteins, such as protamine sulfate, platelet factor-4, and beta-thromboglobulin.

22 disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies.

23 thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.

24 e Western blotting of factor V, prothrombin, platelet factor 4, antithrombin III, and fibrinogen.

25 kines, PBP (platelet basic protein) and PF4 (platelet factor 4), are within 5.3 kilobases (kb) of eac

26 Platelet factor 4, beta-thromboglobulin (betaTG), platel

27 The alpha-granule proteins platelet factor 4, beta-thromboglobulin, and platelet-de

28 role for platelets and their products (e.g., platelet factor 4, beta-thromboglobulin, RANTES, thrombo

29 We now show that platelet factor 4 binds to monocytes and forms antigenic

30 n has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most

31 shown that antibodies reactive with heparin-platelet factor 4 complexes lead to FcgammaRIIA-mediated

32 se assay (SRA) and for antibodies to heparin/platelet factor 4 complexes with an ELISA.

33 7082, or TPCA-1) or by genetic manipulation (platelet factor 4 Cre:IKK-beta(flox/flox)), blocked SNAP

34 Platelet factor 4-Cre-mediated deletion of Slp-76 is suf

35 t survival and decreased plasma thromboxane, platelet factor 4 (CXCL4), and IFN-gamma.

36 tion factor (M-CSF), and chemokines, such as platelet factor 4 (CXCL4).

37 t is for GAG, its binding is not competed by platelet factor 4/CXCL4, and it is present on cells that

38 Platelet factor 4 did not correlate.

39 While the biological basis of platelet factor 4 expression has been pursued by others,

40 lasmic maturation (ie, glycoprotein GPIb and platelet factor 4 expression) and reduced the ability of

41 tibodies show several similarities with anti-platelet factor 4-heparin antibodies and are a potential

42 ted with a high incidence of IgG Abs against platelet factor 4/heparin (PF4/H) complexes by day 6 aft

43 a 4Ts score, rapid particle gel immunoassay (platelet factor 4/heparin [PF4/H]-PaGIA), and serotonin-

44 An ELISA for anti-platelet factor 4/heparin antibodies was performed using

45 Antibodies to the platelet factor 4/heparin complex are a novel, independe

46 We postulated that antibodies to platelet factor 4/heparin complex might contribute to re

47 due primarily to IgG antibodies specific to platelet factor 4/heparin complexes (PF4/Hs) that activa

48 PRT/H Abs showed no cross-reactivity to platelet factor 4/heparin complexes, but were cross-reac

49 heparin therapy caused by antibodies against platelet factor 4/heparin complexes.

50 y antibodies against complexes between human platelet factor 4 (hPF4) and heparin.

51 two positively acting sequences in the human platelet factor 4 (hPF4) gene promoter that synergized t

52 ed a panel of HDPs and determined that human platelet factor 4 (hPF4) kills malaria parasites inside

53 Interactions between heparin, human platelet factor 4 (hPF4), antibodies to the hPF4/heparin

54 transcription-induced release of sCD40L and platelet factor 4 in C57BL/6 mice.

55 Roles of IGFBP-1 and platelet factor 4 in HC.HA antiangiogenic action warrant

56 in the absence of clinical disease, such as platelet factor 4 in heparin-induced thrombocytopenia an

57 by determination of beta-thromboglobulin and platelet factor 4 in the supernatants, platelets bound t

58 0, monokine induced by gamma interferon, and platelet factor 4 inhibit epidermal growth factor (EGF)-

59 At this point, 50% of the platelet factor 4 is released, suggesting that half (app

60 0, monokine induced by interferon gamma, and platelet factor 4, limit fibroblast responsiveness to gr

61 wth-related protein-alpha (Gro-alpha) and to platelet factor-4-M2 (PF4-M2), an N-terminal chimera of

62 PLC-gamma2 and platelet factor 4 mRNA levels were normal.

63 (MIP-1beta), MIP-2, and KC (a member of the platelet factor 4 neutrophil chemoattractant family), as

64 kine C-X-C motif ligand 4 (CXCL4, also named platelet factor 4 or PF4) in the bone marrow, and we fou

65 antimicrobial peptides from human platelets: platelet factor 4 (PF-4), RANTES, connective tissue acti

66 for megakaryocyte specific genes, c-mpl and platelet factor 4 (PF-4).

67 P483H contains the heparin-binding region of platelet factor-4 (PF-4) and a lysine-rich sequence for

68 evidence that changes in platelet-associated platelet factor-4 (PF-4) detect malignant growth across

69 rostate specific membrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the a

70 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interleukin-6 (IL-6) simul

71 , prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4), and interlukin-6 (IL-6).

72 -10, macrophage-derived chemokine [MDC], and platelet factor-4 [PF-4]) to be expressed by CD34(+) cel

73 APC) improves survival in severe sepsis, and platelet factor 4 (PF4) accelerates APC generation in a

74 that monocytes complexed with surface-bound platelet factor 4 (PF4) activated by HIT antibodies cont

75 irected to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H).

76 mediated by antibodies to complexes between platelet factor 4 (PF4) and heparin or cellular glycosam

77 antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan

78 therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.

79 rcoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin.

80 oss-linking of Fc gamma RIIA by anti-heparin/platelet factor 4 (PF4) antibodies is central to the pat

81 Additionally, platelet factor 4 (PF4) binds to bacteria and reduces th

82 arin therapy that is caused by antibodies to platelet factor 4 (PF4) complexed with heparin.

83 Although antibodies to heparin-platelet factor 4 (PF4) complexes are found in essential

84 uires detection of antibodies to the heparin/platelet factor 4 (PF4) complexes via enzyme-linked immu

85 The positively charged chemokine platelet factor 4 (PF4) forms immunogenic complexes with

86 Platelet factor 4 (PF4) is a negative regulator of megak

87 Platelet factor 4 (PF4) is a negative regulator of megak

88 Here we discovered that chemokine platelet factor 4 (PF4) is a negative regulator of Th17

89 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

90 Platelet factor 4 (PF4) is an abundant platelet alpha-gr

91 Platelet factor 4 (PF4) is produced by platelets with ro

92 The platelet-specific chemokine platelet factor 4 (PF4) is released in large amounts at

93 e estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter.

94 Platelet factor 4 (PF4) serves as a lineage-specific mar

95 e ultralarge complexes (ULCs) of heparin and platelet factor 4 (PF4) tetramers.

96 xes between unfractionated heparin (UFH) and platelet factor 4 (PF4) that form over a narrow molar ra

97 tight electrostatic binding of the chemokine platelet factor 4 (PF4) to polyanions induces heparin-in

98 The chemokine platelet factor 4 (PF4) undergoes conformational changes

99 fic for complexes formed between heparin and platelet factor 4 (PF4), a basic protein found normally

100 Therefore, we investigated the effect of platelet factor 4 (PF4), a cationic protein released in

101 Platelet factor 4 (PF4), a platelet alpha-granule protei

102 Platelet factor 4 (PF4), a platelet-derived CXC chemokin

103 Platelet factor 4 (PF4), a platelet-specific chemokine r

104 Platelet factor 4 (PF4), an abundant platelet alpha-gran

105 we used the megakaryocyte-specific promoters platelet factor 4 (PF4), and glycoprotein IIb (GPIIb) as

106 Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibo

107 sorder caused by immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin o

108 exes of platelet activation: platelet count, platelet factor 4 (PF4), beta-thromboglobulin (beta-TG),

109 genes tested, including GPIbalpha, GPIbbeta, platelet factor 4 (PF4), c-mpl, and p45 NF-E2.

110 Immune complexes consisting of platelet factor 4 (PF4), heparin, and PF4/heparin-reacti

111 by four essential components--heparin (Hep), platelet factor 4 (PF4), IgG antibodies against the Hep-

112 neutrophils and have a structure similar to platelet factor 4 (PF4), in which the first two cysteine

113 ific for complexes consisting of heparin and platelet factor 4 (PF4).

114 tiation through the actions of the chemokine platelet factor 4 (PF4).

115 activation, which is further facilitated by platelet factor 4 (PF4).

116 , it forms complexes with positively charged platelet factor 4 (PF4).

117 dies recognize complexes between heparin and platelet factor 4 (PF4).

118 ients with HIT develop autoantibodies to the platelet factor 4 (PF4)/heparin complex, which is termed

119 Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallma

120 othrombotic disorder caused by antibodies to platelet factor 4 (PF4)/heparin complexes.

121 h patients tested strongly positive for anti-platelet factor 4 (PF4)/heparin immunoglobulin (Ig)G in

122 This study demonstrates that a human platelet factor 4 (PF4)/heparin-specific murine monoclon

123 g of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin.

124 ility that immune complexes formed following platelet factor 4 (PF4/CXCL4) binding to anti-PF4 antibo

125 onstrate that the platelet-derived chemokine platelet factor 4 (PF4/CXCL4) stimulates VSMC injury res

126 g to provide direct evidence that tetrameric platelet factor-4 (PF4) and dimeric interleukin-8 (IL8),

127 s overexpression in transgenic mice (via the platelet factor 4 [PF4] promoter) on megakaryocyte devel

128 ting (IL-3) and growth-inhibitory (MIP-1 and platelet factor 4 [PF4]) cytokines, and extracellular ma

129 ration (glycoprotein [GP] Ibalpha, GPIX, and platelet factor 4 [PF4]), whereas GABPalpha-deficient me

130 iomarkers (fractalkine, platelet P-selectin, platelet factor 4 [PF4], and tumor necrosis factor-alpha

131 nfirmed HIT (4Ts score >/=4 points; positive platelet factor 4 [PF4]/heparin immunoassay, positive se

132 Platelet factor 4(PF4), an abundant platelet secretory p

133 (tTA), under the control of the MK-specific platelet factor 4 promoter (PF4-tTA-VP16).

134 or transgene expression to platelets using a platelet factor 4 promoter.

135 mbocytopenia antibody" attaches to a heparin-platelet factor 4 protein complex.

136 osaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing

137 , including neutrophil-activating protein-2, platelet factor-4, RANTES, and macrophage chemotactic pr

138 Serotonin, ADP/ATP, and platelet factor 4 release was profoundly affected in the

139 neration, platelet-derived growth factor and platelet factor 4 release, incorporation of thrombin int

140 tment with rhMIP-1 beta or rhRANTES, but not platelet factor-4, resulted in improved thymic homing of

141 and effectiveness of intravenous recombinant platelet factor 4 (rPF4) as an alternative to protamine

142 well as platelet-derived molecules including platelet factor 4, serotonin, P-selectin, and CD154 (CD4

143 cretable form of the antiangiogenic protein, platelet factor 4 (sPF4).

144 hemokines, monokine induced by IFN-gamma and platelet factor 4 that also generate cAMP, inhibited EGF

145 l expressed and secreted, RANTES) and CXCL4 (platelet factor 4) to the monocyte surface and endotheli

146 GA6, and increased plasma concentrations of platelet factor 4 under basal conditions.

147 otein convertase subtilisin/kexin type 9 and platelet factor-4, whereas they had a minimal inhibitory

148 n PEDF and TSP-1 but did contain IGFBP-1 and platelet factor 4 while significantly suppressing neovas

149 CL4L1, is a homologue of CXCL4 chemokine (or platelet factor 4) with potent anti-angiogenic activity